Tom Schwarz

LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies.

Erasmus Medical Center (Private Equity) (Erasmus MC-PE) is the private equity division of Erasmus MC in The Netherlands. Established in 1998 as the Erasmus Medical Centerby the Dean of the faculty and the Boards of the Erasmus University Rotterdam, they became Erasmus MC in 2002. The Erasmus MC Biomedical Fund BV investment team is based in Rotterdam, and invests in seed and early-stage firms in the life science sector.

Corgo NV specializes in corporate consulting services. The company determines the required profiles for client’s new directors, engages a network of professional external directors, recommends suitable candidates, and refers search specialists. It was founded by Karel Plasman in 2003 and is headquartered in Brussels, Belgium.

Regenesance BV develops drugs for the treatment of neurodegenerative and immune mediated disorders. Its products include Regenemab, a monoclonal antibody for multiple indications like PNH, myasthenia gravis, amyotrophic lateral sclerosis, and multiples sclerosis. The company was founded by Valeria Ramaglia, Mikael Orum, Frank Baas and Kees Fluiter in 2009 is headquartered in Amsterdam, the Netherlands.

Micronit Microfluidics BV designs, develops and manufactures custom made microfluidic components based on micro- and nanotechnology. The firm’s products include droplet generators, microreactors, flow cells, micromixers, chip holders and connections, electrical impedance spectropscoy (EIS) chips and microfluidic starter kit. The company was founded by Ronny van ‘t Oever in 1999 and is headquartered in Enschede, the Netherlands.

AIMM Therapeutics BV develops therapeutic antibodies for the treatment of cancer and infectious diseases. Its antibody discovery platform couples proprietary knowledge of B cell immortalization with the isolation of antibodies from humans or animals. The company was founded by Donald Kalff and Hergen Spits in 2004 and is headquartered in Amsterdam, the Netherlands.

20Med Therapeutics BV operates as a biomedical company. It focuses on the development of biodegradable materials for biomedical applications and multifunctional nanosystems for controlled drug and gene delivery. The company was founded by Johan F. J. Engbersen in 2011 and is headquartered in Enschede, the Netherlands.